Full Press Release Details
Medical Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial
Readiness in Europe, the Middle East, and Asia (EMEA)
of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent
Full Market Release in the U.S.
physician interest at recent Society of Interventional Radiology conference and rising awareness across markets outside the U.S.
supports commercial readiness throughout heavily populated regions
Mass., April 30, 2026 -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular
Robotic System, is continuing to implement its growth strategy with the appointment of Alon Tamir as Vice President of Sales, Europe,
the Middle East and Asia (EMEA). The Company will continue to prioritize its commercial efforts in the U.S. market, while establishing
regulatory, operational, and commercial core capabilities required to enter international markets. The Company's approach for
EMEA will leverage the successful commercial launch of the LIBERTY system to expand into key international markets,
either by utilizing its FDA clearance or through the CE mark, which is expected by the end of this year. In this capacity, Mr. Tamir
will lead the development and execution of a comprehensive EMEA sales strategy, including go-to-market strategies, distribution, and
strategic partnerships, new product launches tailored to market needs, and regulatory requirements across the region.
Mr. Tamir brings over two decades of experience in
medical technology, with a successful track record of translating strategic vision into measurable impact. The EMEA region represents
a significant growth opportunity. The Company believes Europe alone represents a peripheral endovascular procedure volume comparable
to that of the United States, at approximately 2.3 million procedures, underscoring a significant opportunity for expansion
beyond the U.S. market.
The Company received U.S. Food and Drug Administration
(FDA) clearance for its technology in September 2025 and remains on track with its MDR process, with the anticipation of receiving
a CE mark approval by the end of 2026. The Company also plans to pursue opportunities in countries where it can leverage
its FDA clearance, which may help accelerate international expansion.
"Endovascular robotics is at an inflection
point, and LIBERTY is leading that transformation," commented Alon Tamir, Vice President of Sales, Europe, the Middle East and
Asia (EMEA). "With over two decades of experience across the diagnostic, interventional, and robotics space, I've rarely
seen a technology so well positioned - FDA-cleared, already commercially launched, and now advancing toward CE mark approval. The
opportunity in EMEA is substantial, and I am committed to ensuring we capture it with the same discipline and execution that defined
"As we continue to focus on the U.S. market,
and build on the growing adoption of the LIBERTY System, especially after entering the Full Market Release phase, it is equally
important that we establish a robust commercial readiness strategy in certain international markets, applying the same disciplined
approach that supported our successful execution ahead of commencing commercialization in the U.S.," commented Harel Gadot,
Chairman, CEO and President. "Alon's addition strengthens our ability to expand our presence in key markets outside
the U.S. and advance key distribution and strategic partnerships, leveraging local expertise to ensure a well-coordinated
commercial strategy ahead of regulatory approval in these markets."
Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced
robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic
solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation,
Microbot is driving the future of endovascular care.
more at www.microbotmedical.com and connect on LinkedIn and X.
to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development,
commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including,
but not limited to statements that contain words such as "contemplates," "continues," "could," "forecasts,"
"intends," "may," "might," "possible," "potential," "predicts,"
"projects," "should," "would," "will," "believes," "plans," "anticipates,"
"expects," "estimates" and similar expressions) should also be considered to be forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,
including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY Endovascular
Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory
pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes
in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual
property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors"
in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's
web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements,
except as required by law.